Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Pharma
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
The FDA's outside advisers voted that the early deaths seen in the two CAR-Ts' trials are an acceptable risk compared to the drugs' benefits.
Angus Liu
Mar 15, 2024 1:58pm
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am
Bristol Myers bags FDA nod to bring CAR-T to CLL
Mar 15, 2024 9:46am
Charles River to help Navega produce gene therapy candidate
Mar 14, 2024 9:50am
FDA flags early deaths for multiple myeloma CAR-Ts
Mar 13, 2024 11:06am
Legend CEO offers preview of high-stakes FDA adcomm for Carvykti
Mar 11, 2024 1:29pm
More News
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
Feb 23, 2024 10:15am
Daiichi Sankyo, Astellas, Novartis and more—Fierce Pharma Asia
Feb 23, 2024 8:06am
National Resilience to drop $225M into Ohio facility
Feb 20, 2024 9:20am
FDA approves first T-cell therapy for a solid tumor
Feb 17, 2024 12:15pm
See more stories